Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension

New England Journal of Medicine

Volumn 373, Issue 9, 2015, Pages 834-844

  Galie, N ^a   Barbera, J A ^b   Frost, A E ^c   Ghofrani, H A ^d   Hoeper, M M ^e   McLaughlin, V V ^g   Peacock, A J ^h   Simonneau, G ^j   Vachiery, J L ^k   Grunig, E ^f   Oudiz, R J ^l   Vonk Noordegraaf, A ^o   White, R J ^p   Blair, C ^m   Gillies, H ^m   Miller, K L ^m   Harris, J H N ⁱ   Langley, J ⁱ   Rubin, L J ⁿ  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h Scottish Pulmonary Vascular Unit   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k ERASME HOSPITAL   (Belgium)

^l HARBOR UCLA MEDICAL CENTER   (United States)

^m GILEAD SCIENCES   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF ROCHESTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BRAIN NATRIURETIC PEPTIDE; PLACEBO; TADALAFIL; CARBOLINE DERIVATIVE; PEPTIDE FRAGMENT; PHENYLPROPIONIC ACID DERIVATIVE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PYRIDAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NOSE OBSTRUCTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; WALKING; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; HOSPITALIZATION; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; AGED; CARBOLINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHENYLPROPIONATES; PYRIDAZINES; RISK FACTORS;

EID: 84938823530     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1413687     Document Type: Article

References (26)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493-537.
3. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448-56.
4. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122:156-63.
5. Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014;23:469-75.
6. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-903.
7. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100.
8. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
9. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4.
10. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epo-prostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-9.
11. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-22.
12. McLaughlin V V, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-63.
13. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.
14. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521-30.
15. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012;31:150-8.
16. Sitbon O, Jaïs X, Savale L, et al. Up-front triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-7.
17. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 2006; 24: 63-76.
18. Arif SA, Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 2011; 33: 993-1004.
19. Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci 2009;98:4962-74.
20. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl: S55-S66.
21. Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc 1994;26:1078-81.
22. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
23. Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011; 38: 359-67.
24. Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospi-talization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail 2011; 4: 692-9.
25. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35: 1286-93.
26. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010-9.